Search Results - "Eide, Peter Wold"

Portrait of the PI3K/AKT pathway in colorectal cancer by Danielsen, Stine Aske, Eide, Peter Wold, Nesbakken, Arild, Guren, Tormod, Leithe, Edward, Lothe, Ragnhild A.

“…PI3K/AKT signaling leads to reduced apoptosis, stimulates cell growth and increases proliferation. Under normal conditions, PI3K/AKT activation is tightly…”
Get full text

Long noncoding RNA MIR31HG is a bona fide prognostic marker with colorectal cancer cell‐intrinsic properties by Eide, Peter W., Eilertsen, Ina A., Sveen, Anita, Lothe, Ragnhild A.

“…Elevated miR‐31 expression is associated with poor outcome in colorectal cancer (CRC). Whether the prognostic information is independent of known molecular…”
Get full text

Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer by Bruun, Jarle, Sveen, Anita, Barros, Rita, Eide, Peter W., Eilertsen, Ina, Kolberg, Matthias, Pellinen, Teijo, David, Leonor, Svindland, Aud, Kallioniemi, Olli, Guren, Marianne G., Nesbakken, Arild, Almeida, Raquel, Lothe, Ragnhild A.

“…We aimed to refine the value of CDX2 as an independent prognostic and predictive biomarker in colorectal cancer (CRC) according to disease stage and…”
Get full text

Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases by Kryeziu, Kushtrim, Moosavi, Seyed H, Bergsland, Christian H, Guren, Marianne G, Eide, Peter W, Totland, Max Z, Lassen, Kristoffer, Abildgaard, Andreas, Nesbakken, Arild, Sveen, Anita, Lothe, Ragnhild A

“…Tumor heterogeneity is a primary cause of treatment failure. However, changes in drug sensitivity over time are not well mapped in cancer. Patient-derived…”
Get full text

Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer by Eide, Peter W., Moosavi, Seyed H., Eilertsen, Ina A., Brunsell, Tuva H., Langerud, Jonas, Berg, Kaja C. G., Røsok, Bård I., Bjørnbeth, Bjørn A., Nesbakken, Arild, Lothe, Ragnhild A., Sveen, Anita

“…Gene expression-based subtypes of colorectal cancer have clinical relevance, but the representativeness of primary tumors and the consensus molecular subtypes…”
Get full text

E‐cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models by Bruun, Jarle, Eide, Peter W., Bergsland, Christian Holst, Bruck, Oscar, Svindland, Aud, Arjama, Mariliina, Välimäki, Katja, Bjørnslett, Merete, Guren, Marianne G., Kallioniemi, Olli, Nesbakken, Arild, Lothe, Ragnhild A., Pellinen, Teijo

“…Cell–cell and cell–matrix adhesion proteins that have been implicated in colorectal epithelial integrity and epithelial‐to‐mesenchymal transition could be…”
Get full text

Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity by Smeby, Jørgen, Kryeziu, Kushtrim, Berg, Kaja C.G., Eilertsen, Ina A., Eide, Peter W., Johannessen, Bjarne, Guren, Marianne G., Nesbakken, Arild, Bruun, Jarle, Lothe, Ragnhild A., Sveen, Anita

“…PARP inhibitors are active in various tumour types beyond BRCA-mutant cancers, but their activity and molecular correlates in colorectal cancer (CRC) are not…”
Get full text

Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer by Smeby, Jørgen, Sveen, Anita, Eilertsen, Ina A., Danielsen, Stine A., Hoff, Andreas M., Eide, Peter W., Johannessen, Bjarne, Hektoen, Merete, Skotheim, Rolf I., Guren, Marianne G., Nesbakken, Arild, Lothe, Ragnhild A.

“…TP53 mutations are common in colorectal cancer (CRC). Most TP53 sequencing studies have been restricted to coding regions, but recent studies have revealed…”
Get full text

Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer by Smeby, Jørgen, Sveen, Anita, Bergsland, Christian H, Eilertsen, Ina A, Danielsen, Stine A, Eide, Peter W, Hektoen, Merete, Guren, Marianne G, Nesbakken, Arild, Bruun, Jarle, Lothe, Ragnhild A

“…BackgroundAccumulating evidence suggests immunomodulatory and context-dependent effects of TP53 mutations in cancer. We performed an exploratory analysis of…”
Get full text